SWITCH II: Phase III randomized, sequential, open-label study to evaluate the efficacy and safety of sorafenib-pazopanib versus pazopanib-sorafenib in the treatment of advanced or metastatic renal cell carcinoma (AUO AN 33/11).

Retz, M., Bedke, J., Bögemann, M., Grimm, M.-O., Zimmermann, U., Müller, L., Leiber, C., Teber, D., Wirth, M., Bolenz, C., van Alphen, R., De Santis, M., Beeker, A., Lehmann, J., Indorf, M., Frank, M., Bokemeyer, C., Gschwend, J.E., 2019.

Eur J Canc 107, 37–45. doi:10.1016/j.ejca.2018.11.001

Abstract